Chemotherapy in Non-seminomatous Testicular Tumours Stage I

Publisher Website
Google Scholar
Abstract
Chemotherapy improves the survival rate of patients with disseminated teratoid testicular tumors, but patients without evidence of metastatic spread are not usually given further treatment after retroperitoneal lymphadenectomy because of the high toxicity of most drugs; 10-20% of these patients die later with widespread disease. In an earlier series of 24 patients the survival rate in stage 1 disease was below 70%. Since 1973, the use of adjuvant chemotherapy [mithramycin, vinblastine, actinomycin D, methotrexate] in this group was begun; there have been no relapses.